Accessibility navigation

Diarylmethyl substituted titanocenes: promising anti-cancer drugs

Pampillon, C., Mendoza, O., Sweeney, N.J., Strohfeldt, K. and Tacke, M. (2006) Diarylmethyl substituted titanocenes: promising anti-cancer drugs. Polyhedron, 25 (10). pp. 2101-2108. ISSN 0277-5387

Full text not archived in this repository.

To link to this item DOI: 10.1016/j.poly.2006.01.007


From the reaction of tert-butyl lithium with p-bromo-N,N-dimethylaniline (1a), p-bromoanisole (1b) or 1-bromo-3,5-dimethoxybenzene (1c), p-N,N-dimethylanityl lithium (2a), p-anisyl lithium (2b) or (3,5-dimethoxyphenyl) lithium (2c), respectively, were obtained. When reacted with 6-(p-N,N-dimethylanilinyl)fulvene (3a), 6-(p-methoxyphenyl)fulvene (3b) or 3,5-(dimethoxyphenyl)fulvene (3c), the corresponding lithiated intermediates were formed (4a-c). Titanium tetrachloride was added "in situ", obtaining titanocenes 5a-C, respectively. When these titanocenes were tested against pig kidney carcinoma (LLC-PK) cells, inhibitory concentrations (IC50) Of 3.8 x 10(-5) M, 4.5 x 10(-5) M, and 7.8 x 10(-5) M, respectively, were observed. These values represent improved cytotoxicity against LLC-PK, compared to their ansa-analogues. (c) 2006 Elsevier Ltd. All rights reserved.

Item Type:Article
Divisions:Faculty of Life Sciences > School of Chemistry, Food and Pharmacy > School of Pharmacy
ID Code:13662
Uncontrolled Keywords:anti-cancer drug, cis-platin, titanocene, fulvene, LLC-PK, tert-butyl lithium , TITANIUM DICHLORIDE, ORGANIC-CHEMISTRY, ANSA-TITANOCENES, FULVENES, COMPLEXES, DERIVATIVES, METALLOCENES, CISPLATIN, AGENTS, TRIAL

University Staff: Request a correction | Centaur Editors: Update this record

Page navigation